Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study

Authors: Dejan B Budimirovic, Kelli C Dominick, Lidia V Gabis, Maxwell Adams, Mathews Adera, Linda Huang, Pamela Ventola, Nicole R Tartaglia, Elizabeth Berry-Kravis

Journal: Frontiers in Pharmacology

Year Published: 2021

Background: Fragile X syndrome (FXS), the most common single-gene cause of intellectual disability and autism spectrum disorder (ASD), is caused by a >200-trinucleotide repeat expansion in the 5′ untranslated region of the fragile X mental retardation […]

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M 1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer’s disease

Authors: Pradeep J Nathan, S Babli Millais, Alex Godwood, Odile Dewit, David M Cross, Janet Liptrot, Bharat Ruparelia, Stephen Paul Jones, Geor Bakker, Paul T Maruff, Gregory A Light, Alastair J H Brown, Malcolm Peter Weir, Miles Congreve, Tim Tasker

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Year Published: 2022

Introduction: This study examined the safety and pharmacodynamic effects of selective muscarinic M1 receptor orthosteric agonist HTL0018318 in 60 patients with mild-to-moderate Alzheimer’s disease (AD) on background donepezil 10 mg/day. Methods: A randomized, double-blind, placebo-controlled 4-week […]

Back to Publications